Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Anti-glaucoma Agent

Natural or synthetic Anti-glaucoma Agents relieve or prevent glaucoma, a condition characterized by increased intraocular pressure, excavation, and… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Long‐term intraocular pressure reduction with intracameral polycaprolactone glaucoma devices that deliver a novel anti‐glaucoma agent
Abstract Long‐term treatment of glaucoma, a major leading cause of blindness, is challenging due to poor patient compliance… Expand
  • figure 1
  • figure 3
  • figure 4
  • figure 5
2014
2014
Nipradilol promotes axon regeneration through S-nitrosylation of PTEN in retinal ganglion cells.
Nipradilol (Nip) is registered as an anti-glaucoma agent. More recently, a protective effect of Nip has been demonstrated in… Expand
2014
2014
In vitro characterization of a controlled-release ocular insert for delivery of brimonidine tartrate.
Glaucoma is the second leading cause of blindness in the US. Brimonidine tartrate (BT) is a modern anti-glaucoma agent that is… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2013
2013
Baicalein as a potential anti-glaucoma agent
 
2010
2010
Preparation of ophthalmic formulations containing cilostazol as an anti-glaucoma agent and improvement in its permeability through the rabbit cornea.
To evaluate the pharmacological properties of cilostazol (CLZ), we examined its intraocular pressure (IOP) -lowering effect. CLZ… Expand
  • table 1
  • figure 1
  • table 2
  • figure 3
  • figure 6
Highly Cited
2004
Highly Cited
2004
Synthesis of prostaglandin F ethanolamide by prostaglandin F synthase and identification of Bimatoprost as a potent inhibitor of the enzyme: new enzyme assay method using LC/ESI/MS.
Prostaglandin (PG) D(2) ethanolamide (prostamide D(2)) was reduced to 9alpha,11beta-PGF(2) ethanolamide (9alpha,11beta-prostamide… Expand
2004
2004
Delayed onset diffuse lamellar keratitis following enhancement LASIK surgery
  • K. Buxey
  • Clinical & experimental optometry
  • 2004
    • Corpus ID: 21521326
Background: Diffuse lamellar keratitis (DLK) is a relatively uncommon complication of the refractive procedure, laser‐assisted in… Expand
Highly Cited
2000
Highly Cited
2000
Stability indicating HPTLC determination of timolol maleate as bulk drug and in pharmaceutical preparations.
Timolol was the first beta blocker to be used as an anti-glaucoma agent and to date remains as the standard because none of the… Expand
1993
1993
[The clinical evaluation of UF-021, a new prostaglandin related compound, in low tension glaucoma patients].
We administered UF-021 isopropyl unoprostone (Rescula) ophthalmic solution, a new prostaglandin-related compound developed as an… Expand
1992
1992
[The intraocular pressure lowering effects of UF-021, a novel prostaglandin related compound, in animals].
The ophthalmic solution of UF-021, a novel prostaglandin (PG) related compound, was investigated for its intraocular pressure… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE